home / stock / kmph / kmph news


KMPH News and Press, KemPharm Inc From 09/23/21

Stock Information

Company Name: KemPharm Inc
Stock Symbol: KMPH
Market: NASDAQ
Website: kempharm.com

Menu

KMPH KMPH Quote KMPH Short KMPH News KMPH Articles KMPH Message Board
Get KMPH Alerts

News, Short Squeeze, Breakout and More Instantly...

KMPH - KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

CELEBRATION, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm...

KMPH - KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

CELEBRATION, Fla., Sept. 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm...

KMPH - KemPharm Appoints Tamara A. Seymour to Board of Directors

CELEBRATION, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair ...

KMPH - SoFi Technologies, Cricut, FIGS among premarket losers' pack

ContextLogic (NASDAQ:WISH) -27% on Q2 earnings release Cricut (NASDAQ:CRCT) -22% on Q2 earnings release Rigel Pharmaceuticals (NASDAQ:RIGL) -18% after FDA declines to approve fostamatinib COVID-19 EUA LifeMD (NASDAQ:LFMD) -13% on Q2 earnings release Sie...

KMPH - KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2021 Results - Earnings Call Transcript

KemPharm, Inc. (KMPH) Q2 2021 Earnings Conference Call August 12, 2021 04:30 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors Travis Mickle - President and CEO LaDuane Clifton - CFO Conference Call Participants Jonathan Aschoff - ROTH Presentation Operator Good day, and th...

KMPH - KemPharm Reports Second Quarter 2021 Financial Results

Corporate and Regulatory Highlights U.S. Commercial Launch of AZSTARYS™ Initiated on July 21, 2021 Serdexmethylphenidate (SDX) Classified as a Schedule IV Controlled Substance by the DEA Announced Orange Book Listing for Six Patents Covering SDX and Confirmation o...

KMPH - How to Pick the Best Small Cap Biotech Stocks to Buy

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in biotech stocks isn’t for the faint of heart, but with a little research, patience and luck, these can be some of the most lucrative equities on the market. Source: Shutterstock For a bit of backg...

KMPH - KemPharm to Report Second Quarter 2021 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET CELEBRATION, Fla., Aug. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of p...

KMPH - KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

CELEBRATION, Fla., July 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the U.S. commercial launch of AZSTARYS™, a once-daily product for the treatment of ...

KMPH - InvestorNewsBreaks - KemPharm Inc. (NASDAQ: KMPH) Announces $39M Warrant Exchange Offering

KemPharm (NASDAQ: KMPH) , a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, has announced its entry into agreements with certain of its holders of its existing warrants exercisable for 6,117,509 shares of its common stock, in the aggregate....

Previous 10 Next 10